Search clinical trials for: Rituximab-CHOP

Total 3494 results

Assistance Publique - Hôpitaux de Paris

Completed

Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (MAINRITSAN 2)

Microscopic Polyangiitis | Granulomatosis With Polyangiitis | Renal Limited Forms

France
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Refractory Lymphoma | DLBCL | MYD88 Gene Mutation | Relapse | CD79A Gene Mutation | CD79B Gene Mutation
The Lymphoma Academic Research Organisation
Roche Pharma AG

Completed

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) (FLIRT)

Follicular Lymphoma

France
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Indolent Adult Non-Hodgkin... and other conditions

United States
Acrotech Biopharma Inc.
Axis Clinicals Limited

Unknown

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Hematologic Diseases
Sun Yat-sen University

Recruiting

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

China
University Hospital Muenster
Bayer

Active, not recruiting

Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP)

Diffuse Large B Cell Lymphoma

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
Amgen

Completed

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Arthritis, Rheumatoid

United States, Germany, Bulgaria, Hungary, Poland, Estonia
University of Colorado, Denver
Rocky Mountain MS Research Group, LLC

Completed

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate (GATEWAYII)

Multiple Sclerosis

United States
mAbxience Research S.L.
Laboratorio Elea Phoenix S.A.; Libbs Farmacêutica LTDA; Innogene Kalbiotech Pte... and other collaborators

Completed

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Diffuse Large B-cell Lymphoma

Malaysia, Argentina, Colombia, India, South Africa, Philippines, Brazil, Russian Federation, Indonesia, Iran, Islamic Republic of, Mexico, Paraguay
Kuopio University Hospital

Completed

Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital (KuoRituxi1)

Rheumatoid Arthritis

Finland
The Lymphoma Academic Research Organisation

Completed

A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas (Ro-CHOP)

Peripheral T Cell Lymphoma

France
Eli Lilly and Company

Completed

Study of FORTEO Use in Subjects in the Community Setting (DANCE)

Osteoporosis

United States
Hunter College of City University of New York
National Institute on Drug Abuse (NIDA)

Not yet recruiting

Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples (CHP)

HIV Infections | Substance Use

United States
Umeå University
Västernorrland County Council, Sweden

Unknown

Group Sessions and Web-based Treatment Targeting Children With Obesity Age 5-12 Years and Their Families (Webcop)

Childhood Obesity

Sweden
Narendranath Epperla
Eli Lilly and Company

Not yet recruiting

Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research...

Completed

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
Pusan National University Hospital

Unknown

Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over

Diffuse Large B-cell Lymphoma
University of Washington
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal...

United States
Regina Elena Cancer Institute

Recruiting

Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment (AATF/Che-1)

Multiple Myeloma

Italy
University of Colorado, Denver
American Pecan Council

Completed

Effects of Pecan Nut Snacks v Equicaloric Snacks on Appetite, Food Intake, Metabolism, Hormones and Biomarkers

Overweight and Obesity

United States
Herlev Hospital
GENIS

Terminated

Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN) (CHITIN)

Advanced Solid Tumors

Denmark
Oral Health Centre of Expertise in Western Norway
University of Bergen; Norwegian University of Science and Technology

Recruiting

Caries-Obesity Prevention in Children by Modifying Risk Behaviors Among Parents With Immigrant Background-COP Study (COP)

Oral Health

Norway
Samsung Medical Center

Completed

Samsung Medical Center-Lymphoma Cohort Study (SMC-LCS)

Lymphoma

Korea, Republic of
University of Illinois at Chicago
Abbott Nutrition

Completed

Rehydration Following Exercise-Induced Dehydration

Dehydration Related to Exercise

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Hunter College of City University of New York
National Institute on Drug Abuse (NIDA)

Completed

Couples Health Project: Couples-based Intervention to Reduce Drug Use and HIV Transmission Risk (CHP)

Risk Behavior | Drug Use | Sex, Anal

United States
National Cancer Institute (NCI)

Completed

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 Positive

United States
Swiss Group for Clinical Cancer Research

Completed

Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma

Lymphoma

Switzerland
University Hospital Heidelberg

Unknown

Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma

CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma

Germany
University of Wisconsin, Madison
Genentech, Inc.

Withdrawn

Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant

End Stage Renal Disease

United States
PETHEMA Foundation

Completed

Rituximab Combined With Chemotherapy in Burkitt's Lymphoma

Acute Lymphoblastic Leukemia | Burkitt's Lymphoma

Spain
Genentech, Inc.

Completed

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Puerto Rico, South Africa
Biogen

Completed

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Sweden, Czech Republic, France, Russian Federation, Turkey, United Kingdom, Germany, Lithuania, Romania, United States, Austria
Rambam Health Care Campus
Technion, Israel Institute of Technology

Unknown

Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab

Lymphoma
University of Alabama at Birmingham

Completed

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

Purpura, Thrombocytopenic, Idiopathic

United States
Charite University, Berlin, Germany
Hoffmann-La Roche

Unknown

Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis

Ankylosing Spondylitis

Germany
Sandoz
Hexal AG

Completed

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT)

Rheumatoid Arthritis

United States, Germany, Poland, Hungary
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Lymphoma

United States
Lymphoma Study Association
Amgen

Terminated

ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Lymphoma

United States, Canada
Dong-A University Hospital

Completed

Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)

Lymphoma

Korea, Republic of
University of California, San Francisco

Completed

Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

Lymphoma | Brain and Central Nervous System Tumors

Search clinical trials for: Rituximab-CHOP

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations